Neonatal antibodies are detected in cord blood after vaccination of pregnant woman with the inactivated SARS-CoV-2 vaccine: A case report

Year 2023, Volume: 20 Issue: 4, 2027 - 2030, 31.12.2023

Zeynep Asli Oskovi Kaplan , A. Seval Özgü-erdinç , Gul Nihal Buyuk , Eda Üreyen Özdemir , Cüneyt Tayman , Bedia Dinç , Özlem Moraloğlu Tekin

https://doi.org/10.38136/jgon.1083930

Abstract

Studies evaluating the safety and efficacy of currently available vaccines for SARS-CoV-2 do not include pregnant women and newborns. Safety data for vaccinating pregnant women with the COVID-19 vaccine is urgently needed since the vaccine is the only way to protect the vulnerable population. The 33 years-old pregnant women, a healthcare worker as an obstetrician and gynecologist, was vaccinated with inactivated SARS-CoV-2 vaccine with two doses within 28 days apart as the recommended protocol, on her 29th week and 33rd week of pregnancy. The rest of the pregnancy was uneventful and she gave birth on the 38th week to a healthy infant. The infant was a healthy boy upon first evaluation. Maternal blood was sampled immediately after birth, cord blood was obtained from a neonate for the immunoglobulin testing method. COVID-19 IgG and IgM antibodies for spike antigen was reported maternal as 2.04 (reactive) and the cord blood as 1.36 (reactive in a low titration). In this case we report an infant with SARS-CoV-2 IgG and IgM antibodies detectable in cord blood after maternal vaccination with inactivated vaccine.

Keywords

COVID-19, Cord blood, Maternal, Newborn, Vaccination

Supporting Institution

None

İnaktif SARS-CoV-2 aşısı olan gebenin bebeğinin kord kanında antikor saptanması: Olgu sunumu

Abstract

SARS-CoV-2 için şu anda mevcut aşıların güvenliğini ve etkinliğini değerlendiren çalışmalar hamile kadınları ve yenidoğanları içermiyor. Gebe kadınları COVID 19 aşısı ile aşılamak için güvenli verilere acilen ihtiyaç duyulmaktadır, çünkü aşı savunmasız nüfusu korumanın tek yoludur. 33 yaşındaki kadın hastalıkları ve doğum uzmanı sağlık çalışanı gebeye 29.hafta ve 33.haftada önerilen protokolde 28 gün arayla iki doz inaktive SARS-CoV-2 aşısı yapıldı. Hamileliğinin geri kalanı sorunsuz geçti ve 38. haftada sağlıklı bir bebek dünyaya getirdi. Yenidoğan ilk değerlendirmesinde sağlıklı olarak izlendi. Doğumdan hemöen sonra anne kanı ve yenidoğandan kordon kanı, immünoglobulin test yöntemi için alındı. Spike antijeni için COVID-19 IgG ve IgM antikorları maternal 2,04 (reaktif) ve kordon kanı 1,36 (düşük titrasyonda reaktif) olarak rapor edilmiştir. Bu vakada, inaktif aşı ile annenin aşılanmasından sonra kordon kanında saptanabilen SARS-CoV 2 IgG ve IgM antikorları olan bir yenidoğan bildiriyoruz.

Keywords

COVID-19, kord kanı, anne, yenidoğan, aşı

References

• Dey M, Singh S, Tiwari R, Nair VG, Arora D, Tiwari S. Pregnancy Outcome in First 50 Sars-Cov-2 Positive Patients At Our Center. Gynecol Obstet Reprod Med. 2021:1-6.
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589-93.
• Palacios R, Patino EG, de Oliveira Piorelli R, Conde M, Batista AP, Zeng G, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853.
• Stafford IA, Parchem JG, Sibai BM. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. Am J Obstet Gynecol. 2021.
• Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel, Switzerland). 2021;11.
• Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases. 2021.
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases. 2021;21:181-92.
• Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021.
• Rottenstreich A, Zarbiv G, Oiknine-Djian E, Zigron R, Wolf DG, Porat S. Efficient maternofetal transplacental transfer of anti- SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021.
• Paul G, Chad R. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report. BMC pediatrics. 2021;21:138.